药理学与化学生物学学科是我国最早的博士学位授予点之一，也是国家第一批临床药理学研究基地。在金正均教授等一批德高望重的老前辈的创建和指引下，药理学与化学生物学学科规模逐渐发展，成为国家“211工程”、“985工程”和上海市“双一流”暨“地方高水平建设项目”重点学科，“药理与毒理学”ESI排名位居全球前1‰行列。
学科坚持人才为先，育引并举的策略，一大批中青年优秀教师和科研学术骨干脱颖而出，形成了一支和谐、充满干劲和凝聚力的创新团队, 在建设中不断育引优秀人才，在教学与科研并重发展中造就创新人才，逐步形成“集聚、适变、开放、共赢”文化氛围。与加拿大多伦多大学、美国明尼苏达大学、澳大利亚莫纳什大学、法国巴黎五大、巴黎七大和里昂一大等建立了密切的学术与人员交流合作，不断提升学科的学术竞争力和国际化水平。
学科目前共有人员34人，其中高级职称人员23人，包含6位PI研究人员，国务院学科评议组成员1人，国家高层次人才计划2人，国家自然科学基金会优秀青年基金获得者2人，上海市优秀学科带头人1人，上海市高校东方学者特聘教授2人，上海市高层次人才计划 1人，上海市科技启明星3人，上海市浦江人才3人，上海市扬帆人才1人等。
学科瞄准生物医药前沿领域和国家科技战略需求开展药理学、化学生物学、纳米药物递送和转化医学研究,主要包括神经退行性病、肿瘤和心脑血管疾病新靶点发现和创新药物研发，药物动力学和药物代谢组学研究，基于疾病功能基因组学信息的化学生物学研究和重大慢病防治的新药与创新生物技术的临床转化等。近五年，主持国家重点基础研究（973计划）课题2项、国家“重大新药创制”重大专项5项、科技部国际科技合作专项4项，国家自然科学基金项目国际合作专项1项、国家自然科学基金项目50余项以及上海市重大/重点课题等10余项。先后在Nat Med, Cell Metab, PNAS, Nat Commun, ACS nano, Adv Funct Mater, Adv Sci, Mol Pharmacol等SCI杂志上发表论文200余篇。成果获上海市科学技术奖一等奖、教育部科技进步奖一等奖、教育部自然科学奖二等奖、上海医学科技奖二等奖和中华医学科技二等奖等，申请国际和国家发明专利30余项，拥有自主知识产权的国家“重大新药创制”在研新药2个。
学科支撑上海市转化医学协同创新中心、国家药品临床试验机构I期临床药物动力学研究室、国家科技部精神神经新药GCP平台药物代谢组学和药动学实验室以及上海市高校系统药理学重点实验室等。拥有多个实验平台，包括分子影像学平台，由共聚焦显微镜、荧光显微镜等构成，满足在各种层次分析细胞影像的需求；药动学与代谢组学平台，由多台超高效液相色谱串联三重四极杆质谱及高分辨质谱构成，能够完成临床药物代谢动力学、代谢组学、脂质组学等分析实验；动物行为学实验平台，由水迷宫、旷场等行为学仪器及分析软件等构成，能够完成动物学习记忆、情绪及运动行为分析等实验；小动物影像平台，由全自动脑立体定位系统、小动物PET/CT等构成，为利用动物模型进行研究提供了保障；药物靶标发现与新药筛选平台，由BIACORE分子互作、ITC等温滴定量热仪、Flexstation III钙流分析仪、PHERAstar、FDSS高速成像分析仪等组成，为新靶标的发展与验证以及分子、细胞水平的高通量筛选及活性测定提供了充分条件；化学信息学与生物信息学平台，由中央随机化系统、电子数据采集与查询管理系统和统计分析系统等组成，实现了更高效便捷的进行数据、计算和图形等资源共享，方便了信息处理工作的进行；纳米生物学平台，由粒度仪、超速离心系统等纳米生物学相关设备构成，为开展纳米生物学研究提供了条件。上述实验平台均有专业技术人员管理和操作，确保科研工作的顺利开展。
The Discipline of Pharmacology and Chemical Biology
The Discipline of Pharmacology and Chemical Biology is one of the earliest doctoral degree awarding points in China, and it is also the first batch of China clinical pharmacology research bases. Established by and under the guidance of a group of highly respected senior researchers such as Professor Jin Zhengjun, the scale of Discipline of Pharmacology and Chemical Biology has gradually expended and the academic level is continuously improved. It is listed in the China National “211 Project” and “985 Project” and Shanghai Key Subject of “Double First Class”and "Local High-Level Construction Project". The ESI of "Pharmacology and Toxicology" ranks the top 1‰in the world.
The Discipline adheres to the strategy of Talent First with Fostering Talents from Inside as well as Introducing Talents from Outside. A large number of outstanding young teachers and scientific researching academics stand out, forming a harmonious, energetic and cohesive innovation team. During the development process, the Discipline continuously attracts and fosters excellent talents, creating innovative talented people in the atmosphere of paying equal attention to scientific research and teaching, and gradually forms a cultural of “Aggregation, Adaptability, Openness, and Win-Win”. The Discipline has established close academic and personnel exchanging and cooperation relationships with University of Toronto, University of Minnesota, Monash University, Paris Descartes University, Paris Diderot University – Paris 7 and Claude Bernard University Lyon 1, etc., and is constantly improving the academic competitiveness and internationalization level.
The discipline currently has a total of 34 personnel, including 23 senior titles, including 6 PI researchers. There are 1 member from the China State Council Discipline Review Group, 2 member from the National High-level Talent Program, 2 Outstanding Young Fund winners of the National Natural Science Foundation of China, 1 Shanghai Outstanding Academic Leader, 2 Special Engaged Professors (Oriental Scholars) of Shanghai colleges and universities, 1 Young Oriental Scholars of Shanghai colleges and universities, 3 members from Shanghai Science and Technology Development Funds, 3 members from Shanghai Pujiang Talent Plan, and 1 member from the Sailing Talent Program, etc.
The subject aims at the frontier fields of biomedicine and national scientific and technological strategy needs to carry out pharmacology, chemical biology, nano drug delivery and translational medical research, mainly including the discovery of new targets for neurodegenerative diseases, tumors and cardio-cerebrovascular diseases and the development of innovative drugs, drug power research on pharmacology and drug metabolomics, chemical biology research based on disease functional genomics information and clinical transformation of new drugs and innovative biotechnology for the prevention and treatment of major chronic diseases. In the past five years, the Discipline has presided over 2 National Programs on Key Basic Research Projects (973 Program), 5 major projects of the National “Major New Drug Creation Projects”, 4 international science and technology cooperation special projects of the Ministry of Science and Technology of P.R.C., 1 international cooperation special project of the National Natural Science Foundation of China, more than 50 projects of the National Natural Science Foundation of China, and more than 10 major/key Shanghai science and technology projects. It has published more than 200 papers in SCI magazines such as Nat Med, Cell Metab, PNAS, Nat Commun, ACS nano, Adv Funct Mater, Adv Sci, and Mol Pharmacol, etc. The scientific research achievements win the First Prize of Shanghai Science and Technology Progress Award, the First Prize of Science and Technology Progress of Ministry of Education, the Second Prize of Natural Science of Ministry of Education, the Second Prize of Shanghai Medical Science and Technology Award, and the Second Prize of Chinese Medical Science and Technology. It has applied for more than 30 international and national invention patents, and has two researching new drugs with independent intellectual property rights of the national "New Major Drug Creation".
The Discipline of Pharmacology and Chemical Biology supports Shanghai Collaborative Innovation Center for Translational Medicine, Phase I Clinical Pharmacokinetics Laboratory of the National Drug Clinical Trial Institute, Pharmacokinetics and Pharmacokinetics Laboratory of the New Neuropsychiatric Drug GCP Platform of the Ministry of Science and Technology, and Shanghai University System Pharmacology Key Laboratory etc. The subject has multiple experimental platforms, including molecular imaging platforms, composed of confocal microscopes, fluorescent microscopes, etc., to meet the needs of analyzing cellular images at various levels; pharmacokinetic and metabolomics platforms, consisting of multiple ultra-high performance liquid phases Chromatography tandem triple quadrupole mass spectrometry and high-resolution mass spectrometry can be used to complete clinical pharmacokinetics, metabolomics, lipidomics and other analytical experiments; animal behavioral experiment platform is composed of water maze, open field and other behavioral instruments and The analysis software and other components can complete the experiments of animal learning and memory, emotion and sports behavior analysis; The small animal imaging platform is composed of a fully automatic brain stereo positioning system and small animal PET / CT, etc., which provides a guarantee for the use of animal models for research; drug target discovery and new drug screening platform, by BIACORE molecular interaction, ITC isothermal titration The instrument, Flexstation III calcium flow analyzer, PHERAstar, FDSS high-speed imaging analyzer, etc., provide sufficient conditions for the development and verification of new targets and high-throughput screening and activity determination at the molecular and cellular levels; Chemoinformatics and Bioinformatics Platform is composed of a central randomization system, an electronic data collection and query management system, and a statistical analysis system，it realizes more efficient and convenient resource sharing of data, calculations, and graphics, and facilitates the process of information processing; nanobiology platform consists of nanometer biology related equipment such as particle size analyzer and ultracentrifuge system, which provides the conditions for carrying out nanobiology research. The above experimental platforms are managed and operated by professional technicians to ensure the smooth development of scientific research.
